The blast progenitors in acute myelogenous leukemia grow in response to hematopoietic growth factors (HGFs), and their sensitivity to antileukemic drugs is influenced by HGFs. We report the effects of stem cell factor (SCF) on the growth and sensitivity to 1-beta-D-arabinofuranosylcytosine (Ara-C) of blast progenitors in acute myelogenous leukemia. SCF stimulated both colony formation and self-...

PURPOSE To report a patient who was referred for orbital cellulitis but was finally diagnosed with acute leukemia. CASE REPORT A 17-year-old boy presented with fever, periorbital erythema and swelling mimicking periorbital cellulitis. He underwent empiric antibiotic therapy. Complete blood counts revealed leukocytosis with a predominance of immature blast cells. Bone marrow aspiration confirm...

Six cases of acute leukemia that underwent lineage switch from acute lymphocytic leukemia to acute myelogenous leukemia are reported. The mean age of the patients was 24 years. time to conversion was 36 months. and survival after conversion was only 3 months. Of the three cases which showed abnormal metaphases at both diagnosis and conversion. two (cases 2. 5) showed related cytogenetic abnorma...

A cytotoxic common ALL antiserum (CALLA) specific for leukemic cells of most patients with non-T-cel- acute lymphoblastic leukemia (ALL) and of some patients with chronic myelogenous leukemia (CML) in blast crisis has been reproducibly prepared using cell lines for absorption. CALLA reacts with leukemic cells of 110 of 134 patients (82%) with non-T-cell ALL; 1 of 71 (1%) patients with acute mye...

We investigated the significance of p210 and p190 molecular abnormalities in 32 adults with Philadelphia chromosome (Ph)-positive acute leukemia. p210 was detected in 15 patients (47%), p190 in 16 (50%), and both in one (3%). p210 was noted in 11 of 24 patients (46%) with acute lymphocytic leukemia, and in four of eight patients (50%) with acute myelogenous or undifferentiated leukemia. Among 2...

The 2008 World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues introduced a new category for myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Many of these cases present as a myeloproliferative neoplasm, usually with eosinophilia. However, neoplasms associated with rearrangement of PDGFRA can present as acute...

PURPOSE Deforolimus (AP23573), a novel non-prodrug rapamycin analogue, inhibits the mammalian target of rapamycin, a downstream effector of the phosphatidylinositol 3-kinase/Akt and nutrient-sensing pathways. A phase 2 trial was conducted to determine the efficacy and safety of single-agent deforolimus in patients with relapsed or refractory hematologic malignancies. EXPERIMENTAL DESIGN Eligi...

Blood, Vol. 50, No. 1 (July), 1977 115 The specificity of an antiserum (titer 1:500) raised in a monkey against K-562 undifferentiated cells with the Philadelphia chromosome (Ph’) was determined. Antibody-dependent, complement-mediated cytotoxicity was demonstrated for both bone marrow cells and peripheral leukocytes from patients with myelogenous and lymphatic leukemias, but not for mature nor...

the hematological malignancies associated with nephrotic syndrome are mainly hodgkin’s and non-hodgkin’s lymphomas and chronic lymphocytic leukemia. acute myelogenous leukemia (aml) has rarely been described in associated with nephritic syndrome. we report a rare case of acute myelogenous leukemia who presented with nephrotic syndrome. a previously healthy 62-year-old man was admitted in nephro...

Blood, Vol. 50, No. 1 (July), 1977 115 The specificity of an antiserum (titer 1:500) raised in a monkey against K-562 undifferentiated cells with the Philadelphia chromosome (Ph’) was determined. Antibody-dependent, complement-mediated cytotoxicity was demonstrated for both bone marrow cells and peripheral leukocytes from patients with myelogenous and lymphatic leukemias, but not for mature nor...